Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPa-Gastric trial
2024-514879-17-00Phase 3Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Overall survival. Planned start Nov 2025; status: authorised.
02
Drugs
paclitaxel
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-514879-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514879-17-00.